Drugs / Autologous CD34+ hematopoietic progenitor cells
Autologous CD34+ hematopoietic progenitor cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07607197 | Feb 2024 → May 2027 expected | anti-HLA hyperimmunization, end stage renal failure | Hospital Universitari Vall d'Hebron Research Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD34+ hematopoietic progenitor cells | “reinfusion of purified autologous CD34+ hematopoietic progenitor cells collected via peripheral blood leukapheresis” NCT07607197 ↗ |
| Action | Restore | “rebuild the immune system from scratch” NCT07607197 ↗ |
| Modality | Cell therapy | “A comprehensive cell therapy protocol involving intense non-myeloablative lymphodepletion followed by stem cell rescue” NCT07607197 ↗ |
| Route | Intravenous | “intravenous reinfusion of purified autologous CD34+ hematopoietic progenitor cells” NCT07607197 ↗ |